Nkarta (NKTX) Shares Outstanding (2019 - 2026)
Nkarta (NKTX) posted quarterly Shares Outstanding (Entity) of $71.3 million for Q1 2026, little changed year-over-year from $71.0 million in Q1 2025, and little changed quarter-over-quarter from $71.1 million in Q4 2025.
Nkarta (NKTX) Shares Outstanding (2019 - 2026) Analysis & Trends
Nkarta's Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $71.3 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) changed 0.47% year-over-year to $71.3 million; the TTM figure through Mar 2026 stood at $71.3 million (changed 0.47% YoY), while the FY2025 annual figure was $71.1 million, up 0.61% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $71.3 million, roughly flat from $71.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $71.3 million in Q1 2026, with the low at $33.0 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $50.7 million (2024), against an average of $58.4 million.
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) soared 48.26% in 2023, then gained 0.47% in 2026.
- Nkarta's Shares Outstanding (Entity) stood at $48.9 million in 2022, then gained by 0.62% to $49.2 million in 2023, then surged by 43.64% to $70.6 million in 2024, then advanced by 0.61% to $71.1 million in 2025, then climbed by 0.3% to $71.3 million in 2026.
- Business Quant data shows NKTX's Shares Outstanding (Entity) at $71.3 million in Q1 2026, $71.1 million in Q4 2025, and $71.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 74.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.49 Mn |
| Mar 31, 2026 | 74.26 Mn |
| Dec 31, 2025 | 73.99 Mn |
| Sep 30, 2025 | 74.02 Mn |
| Jun 30, 2025 | 73.98 Mn |
| Mar 31, 2025 | 73.92 Mn |
| Dec 31, 2024 | 67.87 Mn |
| Sep 30, 2024 | 73.56 Mn |
| Jun 30, 2024 | 73.49 Mn |
| Mar 31, 2024 | 50.68 Mn |
| Dec 31, 2023 | 49.01 Mn |
| Sep 30, 2023 | 49.06 Mn |
| Jun 30, 2023 | 48.97 Mn |
| Mar 31, 2023 | 48.92 Mn |
| Dec 31, 2022 | 43.63 Mn |
| Sep 30, 2022 | 48.63 Mn |
| Jun 30, 2022 | 43.84 Mn |
| Mar 31, 2022 | 32.99 Mn |
| Dec 31, 2021 | 32.86 Mn |
| Sep 30, 2021 | 32.90 Mn |